The broad-spectrum activity of perampanel: state of the art and future perspective of AMPA antagonism beyond epilepsy
F Perversi, C Costa, A Labate, S Lattanzi… - Frontiers in …, 2023 - frontiersin.org
Glutamate is the brain's main excitatory neurotransmitter. Glutamatergic neurons primarily
compose basic neuronal networks, especially in the cortex. An imbalance of excitatory and …
compose basic neuronal networks, especially in the cortex. An imbalance of excitatory and …
Efficacy and tolerability of antiseizure drugs
T Hakami - Therapeutic advances in neurological disorders, 2021 - journals.sagepub.com
Drug-resistant epilepsy occurs in 25–30% of patients. Furthermore, treatment with a first-
generation antiseizure drug (ASD) fails in 30–40% of individuals because of their intolerable …
generation antiseizure drug (ASD) fails in 30–40% of individuals because of their intolerable …
Progressive myoclonic epilepsy as an expanding phenotype of NGLY1-associated congenital deglycosylation disorder: a case report and review of the literature
Y Sonoda, A Fujita, M Torio, T Mukaino… - European Journal of …, 2024 - Elsevier
bstract Introduction NGLY1-associated congenital disorder of deglycosylation (CDDG1:
OMIM# 615273) is a rare autosomal recessive disorder caused by a functional impairment of …
OMIM# 615273) is a rare autosomal recessive disorder caused by a functional impairment of …
[HTML][HTML] Perampanel enhances the cardiovagal tone and heart rate variability (HRV) in patients with drug-resistant temporal lobe epilepsy
Objective The temporal lobe plays a central role in the regulation of the" Central Autonomic
Network" and cardiovascular functions. The blockade of glutamatergic pathways in the …
Network" and cardiovascular functions. The blockade of glutamatergic pathways in the …
[HTML][HTML] Perampanel for the treatment of epilepsy with genetic aetiology: Real-world evidence from the PERMIT Extension study
Genetic factors contribute to the aetiology of epilepsy in> 50% of cases, and information on
the use of antiseizure medications in people with specific aetiologies will help guide …
the use of antiseizure medications in people with specific aetiologies will help guide …
ILAE Genetics Literacy series: Progressive myoclonus epilepsies
JM Cameron, CA Ellis, SF Berkovic… - Epileptic …, 2023 - Wiley Online Library
Abstract Progressive Myoclonus Epilepsy (PME) is a rare epilepsy syndrome characterized
by the development of progressively worsening myoclonus, ataxia, and seizures. A …
by the development of progressively worsening myoclonus, ataxia, and seizures. A …
[HTML][HTML] Perampanel as only add-on epilepsy treatment in elderly: A subgroup analysis of real-world data from retrospective, multicenter, observational study
A Pascarella, S Gasparini, L Manzo, O Marsico… - Journal of the …, 2023 - Elsevier
Introduction Drug management of epilepsy in the elderly presents unique but data on this
population are scarce. This study aimed to assess the effectiveness and tolerability of …
population are scarce. This study aimed to assess the effectiveness and tolerability of …
Progressive Myoclonus Epilepsy: A Scoping Review of Diagnostic, Phenotypic and Therapeutic Advances
V Zimmern, B Minassian - Genes, 2024 - mdpi.com
The progressive myoclonus epilepsies (PME) are a diverse group of disorders that feature
both myoclonus and seizures that worsen gradually over a variable timeframe. While each of …
both myoclonus and seizures that worsen gradually over a variable timeframe. While each of …
[HTML][HTML] Diagnosis and treatment of late-onset myoclonic epilepsy in Down syndrome (LOMEDS): A systematic review with individual patients' data analysis
Introduction The late onset myoclonic epilepsy in Down Syndrome (LOMEDS) is a peculiar
epilepsy type characterized by cortical myoclonus and generalized tonic-clonic seizures …
epilepsy type characterized by cortical myoclonus and generalized tonic-clonic seizures …
Lafora Disease: A Case Report and Evolving Treatment Advancements
CR Ferrari Aggradi, M Rimoldi, G Romagnoli… - Brain Sciences, 2023 - mdpi.com
Lafora disease is a rare genetic disorder characterized by a disruption in glycogen
metabolism. It manifests as progressive myoclonus epilepsy and cognitive decline during …
metabolism. It manifests as progressive myoclonus epilepsy and cognitive decline during …